

1. Rivellese AA, Riccardi G, Giacco A, Pacioni D, Genovese S, Mattioli PL, Mancini M. Effect of dietary fibre on glucose control and serum lipoproteins in diabetic patients. *LANCET*, vol. 2, p. 447-450, 1980.
2. Fedele D., Lapolla A., Baldo G, Del Prato S., Tiengo A., Crepaldi G. Simfibrate effects on plasma lipids and glucose tolerance in hyperlipoproteinemias. *Current Therapeutic Research* 29, 401-415, 1981.
3. Fedele D., Fellin R., Lapolla A., Baggio G., De Romedi F. Serum lipid and lipoprotein levels and metabolic control in insulin-treated diabetics. *Acta Diabetol. Lat.* 18, 151-159, 1982.
4. Lapolla A., Tessari P., Duner E., Trevisan R., Zordan V., Nosadini R., Tiengo A. Hormonal and metabolic profiles in patients with alcohol-induced mixed hypertriglyceridemia before and after abstinence from ethanol and before and after a lipid-lowering diet. *Atherosclerosis* 60, 151-159, 1986.
5. Postiglione A, Riccardi G, Saldalamacchia G. Hypolipidemic effects of bezafibrate: studies in Italy. *Monogr Atheroscler.* 14:198-202, 1986.
6. Riccardi G, Rivellese AA, Capaldo B, Vaccaro O. Glucose intolerance and plasma lipids. *Diabetes Care*, 212-215, 1986.
7. Annuzzi G, Jansson E, Kaijser L, Holmquist L, Carlson LA. Increased removal rate of exogenous triglycerides after prolonged exercise: time course and effect of exercise duration. *Metabolism* 36(5):438-443, 1987.
8. Wahlberg G, Holmquist L, Walldius G, Annuzzi G. Effects of Nicotinic Acid on Concentrations of Serum Apolipoproteins B, C-I, C-II, C-III and E in Hyperlipidemic Patients. *Acta Medica Scandinavica* 224:319-327, 1988.
9. Rivellese AA, Riccardi G, Romano G, R. Giacco, Patti L, G. Marotta, Annuzzi G, Mancini M. Presence of very low density lipoprotein compositional abnormalities in Type 1 (insulin-dependent) diabetic patients: effects of blood glucose optimisation. *Diabetologia*, 31: 884-888, 1988.
10. Annuzzi G, Holmquist L, Carlson LA. Concentrations of apolipoproteins B, C-I, C-II, C-III, E and lipids in serum and serum lipoproteins of normal subjects during alimentary lipemia. *Scandinavian Journal of Clinical and Laboratory Investigation* 49:73-81, 1989.
11. Tognarelli M, Miccoli R, Giampietro O, Benzi L, Ciccarone A, Giovannitti G, Bertolotto A, Penno G, Navalesi R. Effects of guar-pasta on serum lipid levels in obese diabetic and non-diabetic women with normal lipids. *Acta Diabetol Lat.* 25: 243-6, 1988.

12. Cignarelli M, Cicinelli E, Corso M, Cospite MR, Garruti G, Tafaro E, Giorgino R, Schonauer S. Biophysical and endocrine-metabolic changes during menopausal hot flashes: increase in plasma free fatty acid and norepinephrine levels. *Gynec. Obst. Invest.*; 27: 34-37, 1989.
13. Riccardi G, Genovese S, Saldalamacchia G, Patti L, Marotta G, Postiglione A, Rivellese A, Capaldo B, Mancini M. Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes. *Atherosclerosis*. 75(2-3):175-81, 1989.
14. Annuzzi G, Rivellese A, B. Capaldo, Di Marino L, Iovine C, Marotta G, Riccardi, G. A controlled study on the effects of n-3 fatty acids on lipid and glucose metabolism in non-insulin-dependent diabetic patients. *ATHEROSCLEROSIS*, vol. 87, p. 65-73, 1991.
15. Zambon S., Lapolla A., Sartore G., Gerhardinger C., Cortella A., Manzato E., Crepaldi G., Fedele D. Long-term treatment with simvastatin in type 2 diabetic patients. *Curr Therap Res*. 52 (2), 221-9, 1992.
16. Rivellese, Romano G, Patti L, Annuzzi G, Riccardi G. Persistent lipoprotein composition abnormalities in long-term well controlled insulin-dependent diabetic patients. *Diab. Nutr. Metab*. 5:99-105, 1992.
17. Patti L, Romano G, Di Marino L, Annuzzi G, Mancini M, Riccardi G, Rivellese AA. Abnormal distribution of VLDL subfractions in type 1 (insulin-dependent) diabetic patients: could plasma lipase activities play a role? *Diabetologia* 36:155-160, 1993.
18. Manzato M., Zambon S., Lapolla A., Zambon S., Braghetto L, Crepaldi G., Fedele D. Lipoprotein abnormalities in well-treated type II diabetic patients. *Diabetes Care* 16 (2), 469-475, 1993.
19. Cigolini M., Seidell J.C., Zenti M.G., Bonadonna G., Zambelli L., Deslypere J.P, Contaldo F., Cruz A., Charzewska J., Targher G., Muggeo M. Serum Lp(a) levels in randomized healthy men from different European Countries. *Eur. J. Epidemiol*. 9 (5):497-503, 1993.
20. De Pergola G, Giorgino F, Cospite MR, Giagulli VA, Cignarelli M, Ferri G, Giorgino R. Relation between sex hormones and serum lipoprotein and lipoprotein(a) concentrations in premenopausal obese women. *Arterioscler Thromb*. 13(5):675-9, 1993.
21. Foster D.M., Barret P.H.R., Toffolo G., Beltz W.F., Cobelli C.: Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data. *Journal of Lipid Research* 34: 2193-2205, 1993.

22. Rivellese A, Auletta P, Marotta G, Saldalamacchia G, Giacco A, Mastrilli V, Vaccaro O, Riccardi G. Long term metabolic effects of two dietary methods of treating hyperlipidaemia. *BRITISH MEDICAL JOURNAL*, vol. 308, p. 227-231, 1994.
23. Muggeo M., Zenti M.G., Travia D., Sartori A., Trimeloni S., Grigolini L., Graziani M.S., Cigolini M.. Serum retinol throughout 2 years of cholesterol-lowering therapy. *Metabolism* 44:398-403, 1995.
24. Arcaro G, Zenere BM, Travia D, Zenti MG, Covi G, Lechi A, Muggeo M. Non-invasive detection of early endothelial dysfunction in Hypercholesterolemic subjects. *Atherosclerosis* 114:247-254,1995.
25. Marotta T, Ferrara LA, Di Marino L, Mancini M, Annuzzi G, Russo O, D'Orta G, Lucarelli C, Rossi F. Factors affecting lipoprotein lipase in hypertensive patients. *Metabolism* 44(6):712-718, 1995.
26. Patti L, Di Marino L, Maffettone A, Romano G, Annuzzi G, Riccardi G, Rivellese AA. Very low density lipoprotein subfraction abnormalities in IDDM patients: any effect of blood glucose control? *Diabetologia* 38:1419-1424, 1995.
27. Rivellese AA, Maffettone A, Iovine C, Di Marino L, Annuzzi G, Mancini M, Riccardi G. Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. *Diabetes Care* 19(11):1207-13, 1996.
28. Sirtori CR, Paoletti R, Mancini M, Crepaldi G, Manzato E, Rivellese A, Pamparana F, Stragliotto E. N-3 fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance. Italian Fish Oil Multicenter Study. *AMERICAN JOURNAL OF CLINICAL NUTRITION*, p. 1874-1881, 1997.
29. Romano G, Patti L, Innelli F, Di Marino L, Annuzzi G, Iavicoli M, Coronel GA, Riccardi G, Rivellese AA. Insulin and sulfonylurea therapy in NIDDM patients: are the effects on lipoprotein metabolism different even with similar blood glucose control? *Diabetes* 46: 1601-6, 1997.
30. Patti L, Maffettone A, Iovine C, Di Marino L, Annuzzi G, Riccardi G, Rivellese AA: Long-term effects of fish oil on lipoprotein subfractions and low density lipoprotein size in non insulin-dependent diabetic patients with hypertriglyceridemia. *Atherosclerosis* 146(2): 361-7, 1999.
31. Rivellese, Patti L, Romano G, F. Innelli, Di Marino L, Annuzzi G, M. Iavicoli, G. A. Coronel, Riccardi G: Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients. *J Clin Endocrinol Metab* 85(11):4188-92, 2000.

32. Annuzzi G, Iovine C, B. Mandarino, Patti L, Di Marino L, Riccardi G, Rivellese AA. Effect of acute exogenous hyperinsulinemia on very low density lipoprotein subfraction composition in normal subjects. *European Journal of Clinical Investigation* 31(2):118-24, 2001.
33. Tarugi P, Lonardo A, Gabelli C, Sala F, Ballarini G, Cortella I, Previato L, Bertolini S, Cordera R, Calandra S. Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene. *J Lipid Res* 42(10):1552-61, 2001.
34. Mattock MB, Cronin N, Cavallo-Perin P, Idzior-Walus B, Penno G, Bandinelli S, Standl E, Kofinis A, Fuller JH; EURODIAB IDDM Complications Study. Plasma lipids and urinary albumin excretion rate in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study. *Diabet Med.* 18: 59-67, 2001.
35. Paolisso G, Manzella D, Tagliamonte MR, Barbieri M, Marfella R, Zito G, Bonafè M, Giugliano D, Franceschi C, Varricchio M. The BB-paraoxonase genotype is associated with impaired brachial reactivity after acute hypertriglyceridemia in healthy subjects. *J Clin Endocrinol Metab.* 86(3):1078-82, 2001.
36. Marfella R, De Angelis L, Nappo F, Manzella D, Siniscalchi M, Paolisso G, Giugliano D. Elevated plasma fatty acid concentrations prolong cardiac repolarization in healthy subjects. *Am J Clin Nutr.* 73(1):27-30, 2001.
37. Rivellese A.A., Maffettone A, Vessby B, Uusitupa M, Hermansen K, Berglund L, Louheranta A, Meyer BJ, G. Riccardi. Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects. *ATHEROSCLEROSIS*, vol. 167, p. 149-158, 2003.
38. Irace C, Mancuso G, Fiaschi E, Madia A, Sesti G, Gnasso A. Effect of anti-TNF α therapy on arterial diameter and wall shear stress and HDL cholesterol. *Atherosclerosis* 177: 113–118, 2004.
39. Giacco R, Clemente G, Luongo D, Lasorella G, Fiume I, Brouns F, Bornet F, Patti L, Cipriano P, Rivellese A, Riccardi G. Effects of short-chain fructo-oligosaccharides on glucose and lipid metabolism in mild hypercholesterolaemic individuals. *CLINICAL NUTRITION*, p. 331-340, 2004.
40. Rivellese AA, Vaccaro O, Patti L. The pathophysiology of lipid metabolism and diabetes. *INTERNATIONAL JOURNAL OF CLINICAL PRACTICE*, p. 142-147, 2004.
41. Rivellese, De Natale C, Di Marino L, Patti L, Iovine C, Coppola S, Del Prato S, Riccardi G, Annuzzi G. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. *THE*

JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 89, p. 2153-2159, 2004.

42. Annuzzi G, C De Natale, C Iovine, L Patti, L Di Marino, S Coppola, S Del Prato, G Riccardi, AA Rivellese. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus. *Arterioscler Thromb Vasc Biol.* 24(12):2397-402, 2004.
43. Piarulli F, Lapolla A, Sartore G, Rossetti C, Bax G, Noale M, Minicuci N, Fiore C, Marchioro L, Manzato E, Fedele D Autoantibodies Against Oxidized LDLs and Atherosclerosis in Type 2 Diabetes. *Diabetes Care* 28(3): 653-657, 2005.
44. Montalcini T, Gorgone G, Federico D, Ceravolo R, Emanuele V, Sesti G, Perticone F, Pujia A. Association of LDL cholesterol with carotid atherosclerosis in menopausal women affected by the metabolic syndrome. *Nutr Metab Cardiovasc Dis* 5:368-372, 2005.
45. Lapolla A, Sartore G, Della Rovere G.R, Romanato G, Zambon S., Marin S., Manzato E, Fedele D. Plasma fatty acids and lipoproteins in type 2 diabetic patients. *Diabetes/Metabolism Research and Reviews.* 22:226-231, 2006.
46. Bruno G, Merletti F, Biggeri A, Prina Cerai S, Bargerò G, Pagano G, Cavallo-Perin P. Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with Type 2 diabetes: the Casale Monferrato Study. *Diabetologia*;49:937-944, 2006.
47. Iovine C, Lilli S, Gentile A, Patti L, Di Marino L, Cipriano P, Riccardi G, A. Rivellese. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia. *EUROPEAN JOURNAL OF CLINICAL INVESTIGATION*, vol. 36, p. 560-565, 2006.
48. Barbagallo, C.M., Rizzo, M., Noto, D., Frasheri, A., Pernice, V., Rubino, A., Pieri, D., Giordano C., Notarbartolo A, Aversa, M.R. Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease. *Metabolism: Clinical and Experimental* 55 (5): 662-668, 2006.
49. Riccardi G, Bozzetto L, Annuzzi G. Postprandial lipid metabolism. *Scand J Food Nutr*, 50(S2) 99-106, 2006.
50. Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F. Small, dense low-density lipoprotein and C-reactive protein in obese subjects with and without other criteria for the metabolic syndrome. *J Clin Lipidol.* 1(6):599-604, 2007.

51. Sartore G, Lapolla A, Reitano R, Zambon S, Romanato G, Marin R, Cosma C, Manzato E, Fedele D. Desaturase activities and metabolic control in type 2 diabetes. *Prostaglandins, Leukotrienes and Essential Fatty Acids*. 79:55-58, 2008.
52. Talini E, Di Bello V, Bianchi C, Palagi C, Delle Donne MG, Penno G, Nardi C, Canale ML, Del Prato S, Mariani M, Miccoli R. Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin A preliminary echocardiographic study. *Atherosclerosis*.; 197: 346-354, 2008.
53. Rivellesse AA, Patti L, Kaufman D, Zhu J, Annuzzi G, Vaccaro O, Ebbesson SO, Howard WJ, Riccardi G, Howard BV. Lipoprotein particle distribution and size, insulin resistance, and metabolic syndrome in Alaska Eskimos: The GOCADAN study. *Atherosclerosis*. 200(2):350-8, 2008.
- 54.
55. Annuzzi G. Genetic and environmental modulation of postprandial lipemia: from a better knowledge of the mechanisms to a more effective treatment strategy. *Nutr Metab Cardiovasc Dis*. 18(3):169-72, 2008.
- 56.
57. Rivellesse AA, Giacco R, Annuzzi G, De Natale C, Patti L, Di Marino L, Minerva V, Costabile G, Santangelo C, Masella R, Riccardi G. Effects of monounsaturated vs. saturated fat on postprandial lipemia and adipose tissue lipases in type 2 diabetes. *Clin Nutr*. 27(1):133-41, 2008.
- 58.
59. Annuzzi G, Giacco R, Patti L, Di Marino L, De Natale C, Costabile G, Marra M, Santangelo C, Masella R, Rivellesse AA. Postprandial chylomicrons and adipose tissue lipoprotein lipase are altered in type 2 diabetes independently of obesity and whole-body insulin resistance. *Nutr Metab Cardiovasc Dis*. 18:531-8, 2008.
60. Annuzzi G, Giacco R, Patti L, Bozzetto L, Viscovo D, Rivellesse AA. Low plasma leptin levels in well controlled type 2 diabetes are not related to body fat mass and whole-body insulin resistance. *Nutr Metab Cardiovasc Dis*. 18(7):e35-6, 2008.
61. Rivellesse AA, Bozzetto L, Annuzzi G. Relation between postprandial lipemia, diet, and cardiovascular risk. *Current Cardiovascular Risk Reports* 3:5-11. 2009
62. De Natale C, Annuzzi G, Bozzetto L, Mazzeella R, Costabile G, Ciano O, Riccardi G, Rivellesse AA. Effects of a plant-based high-carbohydrate/high-fiber diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients. *Diabetes Care*. 32(12):2168-73, 2009.

63. Masulli M, Patti L, Riccardi G, Vaccaro O, Annuzzi G, Ebbesson SO, Fabsitz RR, Howard WJ, Otvos JD, Roman MJ, Wang H, Weissman NJ, Howard BV, Rivellese AA. Relation among lipoprotein subfractions and carotid atherosclerosis in Alaskan Eskimos (from the GOCADAN Study). *Am J Cardiol.* 1;104(11):1516-21, 2009.
64. De Natale C, Annuzzi G, Bozzetto L, Mazzarella R, Costabile G, Ciano O, Riccardi G, Rivellese AA. Effects of a plant-based high-carbohydrate/high-fiber diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients. *Diabetes Care.* 32(12):2168-73, 2009.
65. Sartore G, Reitano R, Barison A, Magnanini P, Cosma C, Burlina S, Manzato E, Fedele D, Lapolla A. The effects of psyllium on lipoproteins in type II diabetic patients. *Eur J Clin Nutr.* 63(10):1269-71, 2009.
66. Zoppini G, Targher G, Trombetta M, Lippi G, Muggeo M. Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes. *Obesity.* 17(2):370-4, 2009.
67. Gatti A, Maranghi M, Bacci S, Carallo C, Gnasso A, Mandosi E, Fallarino M, Morano S, Trischitta V, Filetti S. Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes. *Diabetes Care* 32:1550-1552, 2009.
68. Arca M, Cambuli VM, Montali A, Sentinelli F, Filippi E, Campagna F, Quagliarini F, Antonini R, Romeo S, Baroni MG. Serum Adiponectin is decreased in patients with familial combined hyperlipidemia and normolipemic relatives and is influenced by hypolipemic treatment. *Nutrition, Metabolism & Cardiovascular Disease* 10: 660-666, 2009.
69. Stefanutti C., D'Alessandri G., Russi G., De Silvestro G., Zenti M.G., Marson P., Belotherkovsky D, Vivenzo A., Di Giacomo S.. Treatment of symptomatic HyperLa(a)lipoproteinemia with LDL-apheresis: a multi center Study. *Atheroscler suppl.* 10 (5): 89-94; 2009.
70. Annuzzi G, Bozzetto L, Patti L, Santangelo C, Giacco R, Di Marino L, De Natale C, Masella R, Riccardi G, Rivellese AA. Type 2 diabetes mellitus is characterized by reduced postprandial adiponectin response: a possible link with diabetic postprandial dyslipidemia. *METABOLISM, CLINICAL AND EXPERIMENTAL*, vol. 59, p. 567-574, 2010.
71. Succurro E, Arturi F, Grembiale A, Iorio F, Laino I, Andreozzi F, Sciacqua A, Hribal M, Perticone F, Sesti G. Positive association between plasma insulin-like growth factor-1 and HDL cholesterol levels in adult nondiabetic subjects. *Eur J Endocrinol* 163: 75–80, 2010.

72. Stefanutti C. and the Italian Multicenter Study on Low-Density Lipoprotein Apheresis working Group Italian Multicenter Study on Low-Density Lipoprotein Apheresis: Retrospective Analysis (2007). *Therapeutic Apheresis and Dialysis* 14(1):79-86;2010.
73. Annuzzi G, Piscitelli F, Di Marino L, Patti L, Giacco R, Costabile G, Bozzetto L, Riccardi G, Verde R, Petrosino S, Rivellese AA, Di Marzo V. Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. *Lipids in Health and Disease*, 9:43, 2010.
74. Bozzetto L, Annuzzi G, Corte GD, Patti L, Cipriano P, Mangione A, Riccardi G, Rivellese AA. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. *Atherosclerosis*. 217(1):142-8, 2011.
75. Costabile G, Annuzzi G, Di Marino L, De Natale C, Giacco R, Bozzetto L, Cipriano P, Santangelo C, Masella R, Rivellese AA. Fasting and postprandial adipose tissue LPL and HSL in obesity and type 2 Diabetes. *Journal of Endocrinological Investigation*. 34(5):e110-4, 2011.
76. Zenti MG, Stefanutti C. Effects of selective H.E.L.P. LDL-apheresis on plasma inflammatory markers concentration in severe dyslipidemia: Implication for anti-inflammatory response. *Cytokine* 56(3):850-4; 2011.
77. Lapolla A, Manzato E, Sartore G, Marin R, Cosma C, Bolis A, Seraglia R, Traldi P. Evaluation of methionine sulfoxide content of ApoA-I in type 2 diabetic patients and young coronaropathic subjects: a preliminary study. *Rapid Commun Mass Spectrom*. 25(2):391-4, 2011.
78. De Natale C, Minerva V, Patti L, Mazzearella R, Ciano O, Maione S, Luongo D, Naviglio D, Marotta G, Turco S, Ciati R, Melegari C, Rivellese AA, Riccardi G. Effects of baked products enriched with n-3 fatty acids, folates, β -glucans, and tocopherol in patients with mild mixed hyperlipidemia. *J AM COLL NUTR*. 31(5):311-9, 2012.
79. Annuzzi G, Rivellese AA, Wang H, Patti L, Vaccaro O, Riccardi G, Ebbesson SO, Comuzzie AG, Umans JG, Howard BV. Lipoprotein subfractions and dietary intake of n-3 fatty acid: the Genetics of Coronary Artery Disease in Alaska Natives study. *Am J Clin Nutr*. 95(6):1315-22, 2012.
80. Bozzetto L, De Natale C, Di Capua L, Della Corte G, Patti L, Maione S, Riccardi G, Rivellese AA, Annuzzi G. The association of hs-CRP with fasting and postprandial plasma lipids in patients with type 2 diabetes is disrupted by dietary monounsaturated fatty acids. *Acta Diabetol*. 50(2):273-6, 2013.

81. Seraglia R, Sartore G, Marin R, Burlina S, Manzato E, Ragazzi E, Traldi P, Lapolla A. An effective and rapid determination by MALDI/TOF/TOF of methionine sulfoxide content of ApoA-I in type 2 diabetic patients. *J Mass Spectrom.* 48:105-110, 2013.
82. Sartore G, Burlina S, Ragazzi E, Ferraresso S, Valentini R, Lapolla A. Mediterranean diet and red yeast rice supplementation for the management of hyperlipidemia in statin-intolerant patients with or without type 2 diabetes.. *Evidence-Based Complementary and Alternative Medicine*, 2013.
83. Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, Wanner C, Al-Rubeaan K, Aronson R, Barzon I, Bishop L, Bonora E, Bunnag P, Chuang LM, Deerochanawong C, Goldenberg R, Harshfield B, Hernández C, Herzlinger-Botein S, Itoh H, Jia W, Jiang YD, Kadowaki T, Laranjo N, Leiter L, Miwa T, Odawara M, Ohashi K, Ohno A, Pan C, Pan J, Pedro-Botet J, Reiner Z, Rotella CM, Simo R, Tanaka M, Tedeschi-Reiner E, Twum-Barima D, Zoppini G, Carey VJ. Association between plasma triglycerides and HDL-cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes: a global case-control study in 13 countries. *Circulation* 129: 999-1008, 2014.
84. Annuzzi G, Bozzetto L, Costabile G, Giacco R, Mangione A, Anniballi G, Vitale M, Vetrani C, Cipriano P, Della Corte G, Pasanisi F, Riccardi G, Rivellese AA. Diets naturally rich in polyphenols improve fasting and postprandial dyslipidemia and reduce oxidative stress: a randomized controlled trial. *AM J CLIN NUTR.* 99(3):463-71, 2014.
85. Griffo E, Di Marino L, Patti L, Bozzetto L, Annuzzi, Cipriano P, Mangione A, Della Pepa G, Cocozza S, Riccardi G, Rivellese AA. Test meals rich in marine long-chain n-3 polyunsaturated fatty acids increase postprandial chylomicron response. *Nutrition Research.* 34(8):661-6, 2014.
86. Bondia-Pons I, Poho P, Bozzetto L, Vetrani C, Patti L, Aura A-M, Annuzzi G, Hyotylainen T, Rivellese AA, Orešič M. Isoenergetic diets differing in their n-3 fatty acid and polyphenol content reflect different plasma and HDL-fraction lipidomic profiles in subjects at high cardiovascular risk. *Molecular Nutrition and Food Research*, 58(9):1873-82, 2014.
87. Masserini B, Morelli V, Palmieri S, Eller-Vainicher C, Zhukouskaya V, Cairoli E, Orsi E, Beck-Peccoz P, Spada A, Chiodini I. Lipid abnormalities in patients with adrenal incidentalomas: role of subclinical hypercortisolism and impaired glucose metabolism. *J Endocrinol Invest.* 38:623-8, 2015.
88. Penno G, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, Gruden G, Lamacchia O, Pontiroli AE, Arosio M, Orsi E, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Hypertriglyceridemia Is Independently Associated with

- Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. *PLoS One*. 10(5):e0125512, 2015.
- 89.** Salerno A, Fragasso G, Esposito A, Canu T, Lattuada G, Manzoni G, Del Maschio A, Margonato A, De Cobelli F, Perseghin G. Effects of short-term manipulation of serum FFA concentrations on left ventricular energy metabolism and function in patients with heart failure: no association with circulating bio-markers of inflammation. *Acta Diabetol*. 52(4):753-61, 2015.
- 90.** Chillelli NC, Cremasco D, Cosma C, Ragazzi E, Francini Pesenti F, Bonfante L, Lapolla A. Effectiveness of a diet with low advanced glycation end products, in improving glycoxidation and lipid peroxidation: a long-term investigation in patients with chronic renal failure. *Endocrine*. 54(2):552-555, 2016.
- 91.** Di Pino A, Currenti W, Urbano F, Mantegna C, Purrazzo G, Piro S, Purrello F, Rabuazzo AM. Low advanced glycation end product diet improves the lipid and inflammatory profiles of prediabetic subjects. *J Clin Lipidol*. 10(5):1098-108, 2016.
- 92.** Gallo L, Faniello MC, Canino G, Tripolino C, Gnasso A, Cuda G, Costanzo FS, Irace C. Serum Calcium Increase Correlates With Worsening of Lipid Profile: An Observational Study on a Large Cohort From South Italy. *Medicine (Baltimore)*. Feb;95(8):e2774, 2016.
- 93.** Adami GF, Gradaschi R, Andraghetti G, Scopinaro N, Cordera R. Serum Leptin and Adiponectin Concentration in Type 2 Diabetes Patients in the Short and Long Term Following Biliopancreatic Diversion. *Obes Surg*. 26(10):2442-8, 2016.
- 94.** Bozzetto L, Costabile G, Luongo D, Naviglio D, Cicala V, Piantadosi C, Patti L, Cipriano P, Annuzzi G, Rivellese AA. Reduction in liver fat by dietary MUFA in type 2 diabetes is helped by enhanced hepatic fat oxidation. *Diabetologia*. 59(12):2697-2701, 2016.
- 95.** Riccardi G, Vaccaro O, Costabile G, Rivellese AA. How Well Can We Control Dyslipidemias Through Lifestyle Modifications? *Curr Cardiol Rep*. 18(7):66, 2016.
- 96.** Vetrani C, Costabile G, Luongo D, Naviglio D, Rivellese AA, Riccardi G, Giacco R. Effects of whole-grain cereal foods on plasma short chain fatty acid concentrations in individuals with the metabolic syndrome. *Nutrition*. 32(2):217-21, 2016.
- 97.** Göbl CS, Ott J, Bozkurt L, Feichtinger M, Rehmann V, Cserjan A, Heinisch M, Steinbrecher H, JustKukurova I, Tuskova R, Leutner M, Vytiska-Binstorfer E, Kurz C, Weghofer A, Tura A, Egarter C, Kautzky-Willer A. To Assess the Association between Glucose Metabolism and Ectopic Lipid Content in Different Clinical Classifications of PCOS. *PLoS One*. 11(8):e0160571. 2016.

98. Paulmichl K, Hatunic M, Højlund K, Jotic A, Krebs M, Mitrakou A, Porcellati F, Tura A, Bergsten P, Forslund A, Manell H, Widhalm K, Weghuber D, Anderwald CH; Beta-JUDO Investigators.; RISC Investigators. Modification and Validation of the Triglyceride-to-HDL Cholesterol Ratio as a Surrogate of Insulin Sensitivity in White Juveniles and Adults without Diabetes Mellitus: The Single Point Insulin Sensitivity Estimator (SPISE). *Clin Chem.* 62(9):1211-9, 2016.
99. Kahleova H, Malinska H, Kazdova L, Belinova L, Tura A, Hill M, Pelikanova T. The Effect of Meal Frequency on the Fatty Acid Composition of Serum Phospholipids in Patients with Type 2 Diabetes. *J Am Coll Nutr.* 35(4):317-25, 2016.
100. Andreozzi F, Mannino GC, Perticone M, Perticone F, Sesti G. Elevated 1-h post-load plasma glucose levels in subjects with normal glucose tolerance are associated with a pro-atherogenic lipid profile. *Atherosclerosis.* 256:15-20, 2016.
101. Siebel AL, Trinh SK, Formosa MF, Mundra PA, Natoli AK, Reddy-Luthmoodoo M, Huynh K, Khan AA, Carey AL, van Hall G, Cobelli C, Dalla-Man C, Otvos JD, Rye KA, Johansson J, Gordon A, Wong NC, Sviridov D, Barter P, Duffy SJ, Meikle PJ, Kingwell BA. Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial. *Metabolism.* 65(6):904-14, 2016.
102. Nemati R, Lu J, Tura A, Smith G, Murphy R. Acute Changes in Non-esterified Fatty Acids in Patients with Type 2 Diabetes Receiving Bariatric Surgery. *Obes Surg.* 27:649-56, 2017.
103. Blasetti Fantauzzi C, Menini S, Iacobini C, Rossi C, Santini E, Solini A, Pugliese G. Deficiency of the Purinergic Receptor 2X7 Attenuates Nonalcoholic Steatohepatitis Induced by High-Fat Diet: Possible Role of the NLRP3 Inflammasome. *Oxid Med Cell Longev.* 2017:8962458, 2017.
104. Indelicato L, Mariano V, Galasso S, Boscari F, Cipponeri E, Negri C, Frigo A, Avogaro A, Bonora E, Trombetta M, Bruttomesso D. Influence of health locus of control and fear of hypoglycaemia on glycaemic control and treatment satisfaction in people with Type 1 diabetes on insulin pump therapy. *Diabet Med.* 34(5):691-697, 2017.
105. Bertuzzi F, Meneghini E, Bruschi E, Luzi L, Nichelatti M, Epis O. Ultrasound characterization of insulin induced lipohypertrophy in type 1 diabetes mellitus. *J Endocrinol Invest.* 40(10):1107-1113, 2017.
106. Pirro M, Vetrani C, Bianchi C, Mannarino MR, Bernini F, Rivellesse AA. Joint position statement on "Nutraceuticals for the treatment of hypercholesterolemia" of the

- Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). *Nutr Metab Cardiovasc Dis.* 27(1):2-17, 2017.
- 107.** Fiorentino TV, Marini MA, Succurro E, Andreozzi F, Sciacqua A, Hribal ML, Perticone F, Sesti G. Association between hemoglobin glycation index and hepatic steatosis in non-diabetic individuals. *Diabetes Res Clin Pract.* 134:53-61, 2017.
- 108.** Andreozzi F, Mannino GC, Perticone M, Perticone F, Sesti G. Elevated 1-h post-load plasma glucose levels in subjects with normal glucose tolerance are associated with a pro-atherogenic lipid profile. *Atherosclerosis.* 256:15-20, 2017.
- 109.** Radaelli MG, Martucci F, Perra S, Accornero S, Castoldi G, Lattuada G, Manzoni G, Perseghin G. NAFLD/NASH in patients with type 2 diabetes and related treatment options. *J Endocrinol Invest.* 41(5):509-521, 2018.
- 110.** Trovato FM, Castrogiovanni P, Szychlinska MA, Purrello F, Musumeci G. Early effects of high-fat diet, extra-virgin olive oil and vitamin D in a sedentary rat model of non-alcoholic fatty liver disease. *Histol Histopathol.* 33(11):1201-1213, 2018.
- 111.** Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. *Diabetes Care.* 41(2):372-382, 2018.
- 112.** Barchetta I, Cimini FA, Leonetti F, Capoccia D, Di Cristofano C, Silecchia G, Orholm-Melander M, Melander O, Cavallo MG. Increased Plasma Proneurotensin Levels Identify NAFLD in Adults With and Without Type 2 Diabetes. *J Clin Endocrinol Metab.* 103(6):2253-2260, 2018.
- 113.** Nowotny B, Kahl S, Klüppelholz B, Hoffmann B, Giani G, Livingstone R, Nowotny PJ, Stamm V, Herder C, Tura A, Pacini G, Hwang JH, Roden M. Circulating triacylglycerols but not pancreatic fat associate with insulin secretion in healthy humans. *Metabolism.* 81:113-125, 2018.
- 114.** Giorgino F, Shaunik A, Liu M, Saremi A. Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan-L trial. *Diabetes Obes Metab.* 21(12):2712-2717, 2019.
- 115.** Lattuada G, Radaelli MG, De Cobelli F, Esposito A, Manzoni G, Perra S, Del Maschio A, Castoldi G, Perseghin G. Fasting Whole-Body Energy Homeostasis and Hepatic Energy Metabolism in Nondiabetic Humans with Fatty Liver. *Oxid. Med. Cell. Longev.* 2019: 9796175, 2019.
- 116.** Scicali R, Di Pino A, Pavanello C, Ossoli A, Strazzella A, Alberti A, Di Mauro S, Scamporrino A, Urbano F, Filippello A, Piro S, Rabuazzo AM, Calabresi L, Purrello F.

- Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation. *Sci. Rep.*, 9:20354, 2019.
- 117.** Patti AM, Giglio RV, Papanas N, Rizzo M, Rizvi AA. Future perspectives of the pharmacological management of diabetic dyslipidemia. *Expert. Rev. Clin. Pharmacol.*, 12:129-143, 2019.
- 118.** Fogacci F, Grassi D, Rizzo M, Cicero AFG. Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials. *Phytother. Res.*, 33:862-870, 2019.
- 119.** Nikolic D, Corina A, Toth PP, Hammad L, Rizzo M. Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in children. *Expert Opin. Pharmacother.*, 20:241-244, 2019.
- 120.** Nobili V, Mantovani A, Cianfarani S, Alisi A, Mosca A, Sartorelli MR, Maffei C, Loomba R, Byrne CD, Targher G. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. *J Hepatol.* 71(4):802-810. 2019.
- 121.** Zusi C, Mantovani A, Olivieri F, Morandi A, Corradi M, Miraglia Del Giudice E, Dauriz M, Valenti L, Byrne CD, Targher G, Maffei C. Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents. *Dig Liver Dis.* 51(11):1586-1592, 2019.
- 122.** Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. *Int. J. Mol. Sci.*, 20:pii: E1948, 2019.
- 123.** Tedesco S, Adorni MP, Ronda N, Cappellari R, Mioni R, Barbot M, Pinelli S, Plebani M, Bolego C, Scaroni C, Bernini F, Fadini GP, Cignarella A. Activation profiles of monocyte-macrophages and HDL function in healthy women in relation to menstrual cycle and in polycystic ovary syndrome patients. *Endocrine*, 66(2):360-369, 2019.
- 124.** Scicali R, Di Pino A, Urbano F, Ferrara V, Marchisello S, Di Mauro S, Scamporrino A, Filippello A, Piro S, Rabuazzo AM, Purrello F. Analysis of S100A12 plasma levels in hyperlipidemic subjects with or without familial hypercholesterolemia. *Acta. Diabetol.*, 56:899-906, 2019.
- 125.** Marfella R, Amarelli C, Cacciatore F, Balestrieri ML, Mansueto G, D'Onofrio N, Esposito S, Mattucci I, Salerno G, De Feo M, D'Amico M, Golino P, Maiello C, Paolisso G, Napoli C. Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients. *J Am Coll Cardiol.* 75(11):1249-1262, 2020.

126. Ciardullo S, Sala I, Perseghin G. Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016. *Diabetes Res Clin Pract.* 167:108358, 2020.
127. Ciardullo S, Muraca E, Perra S, Bianconi E, Zerbini F, Oltolini A, Cannistraci R, Parmeggiani P, Manzoni G, Gastaldelli A, Lattuada G, Perseghin G. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. *BMJ Open Diabetes Res Care.* 8(1):e000904, 2020.
128. Bozzetto L, Della Pepa G, Vetrani C, Rivellese AA. Dietary Impact on Postprandial Lipemia. *Front Endocrinol (Lausanne).* 11:337, 2020.
129. Fiorentino TV, Succurro E, Sciacqua A, Andreozzi F, Perticone F, Sesti G. Non-alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance. *Diabetes Metab Res Rev.* 36(8):e3333, 2020
130. Rios RS, Zheng KI, Targher G, Byrne CD, Zheng MH. Non-invasive fibrosis assessment in non-alcoholic fatty liver disease. *Chin Med J (Engl).* 133(22):2743-2745, 2020
131. Targher G. Concordance between MAFLD and NAFLD diagnostic criteria in 'real-world' data. *Liver Int.* 40(11):2879-2880, 2020.
132. Zhou YJ, Zheng KI, Ma HL, Li G, Pan XY, Zhu PW, Targher G, Byrne CD, Wang XD, Chen YP, Li XB, Zheng MH. Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD. *Nutr Metab Cardiovasc Dis.* S0939-4753(20)30443-9, 2020.
133. Targher G. What's Past Is Prologue: History of Nonalcoholic Fatty Liver Disease. *Metabolites.* 10(10):397, 2020.
134. Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. *Gut.* gutjnl-2020-322572, 2020.
135. Targher G. Editorial: a diabetologist's perspective on the diagnosis and monitoring of NAFLD. *Aliment Pharmacol Ther.* 52(4):710-711, 2020.
136. Lombardi R, Airaghi L, Targher G, Serviddio G, Maffi G, Mantovani A, Maffei C, Colecchia A, Villani R, Rinaldi L, Orsi E, Pisano G, Adinolfi LE, Fargion S, Fracanzani AL. NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. *J Diabetes Complications.* 34(11):107684, 2020.

- 137.** Mantovani A, Danese E, Salvagno GL, Gelati M, Turino T, Bovo C, Lippi G, Targher G. Association between lower plasma adiponectin levels and higher plasma thrombin generation parameters in men with type 2 diabetes: role of plasma triglycerides. *J Endocrinol Invest*. [Epub ahead of print], 2020.
- 138.** Lu FB, Zheng KI, Rios RS, Targher G, Byrne CD, Zheng MH. Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. *J Gastroenterol Hepatol*. . [Epub ahead of print], 2020.
- 139.** Qiao ZP, Zheng KI, Zhu PW, Gao F, Ma HL, Li G, Li YY, Targher G, Byrne CD, Zheng MH. Lower levels of plasma NT-proBNP are associated with higher prevalence of NASH in patients with biopsy-proven NAFLD. *Nutr Metab Cardiovasc Dis*. 30(10):1820-1825, 2020.
- 140.** Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbaek H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol*. 73(1):202-209, 2020.
- 141.** Lonardo A, Targher G. NAFLD in the 20's. From Epidemiology to Management (PART - II). *Curr Pharm Des*. 26(32):3908, 2020.
- 142.** Lonardo A, Targher G. NAFLD in the 20's. From Epidemiology to Pathogenesis and Management of Nonalcoholic Fatty Liver Disease. *Curr Pharm Des*. 26(10):991-992, 2020.